HealthEquity (HQY) Q2 2027 Earnings Call Transcript
HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations for continued top‑line growth and cash generation, supporting a bullish outlook.
Market read
Strong earnings and raised guidance make HQY a potential buy for traders seeking exposure to fintech‑enabled health‑benefit platforms.
What to watch
Potential regulatory changes to HSA tax treatment and macro health‑care cost inflation.
Background
HealthEquity reported its Q2 FY2027 results, highlighting growth in HSA assets, new advisory services, and AI‑driven cost reductions.
Ticker impact
Q2 FY2027 earnings released with revenue $350.7M (+8% YoY) and raised full-year revenue guidance to $1.411B-$1.421B.
Potential upside as investors price in higher guidance and robust cash flow.
Guidance lift and record adjusted EBITDA margin indicate durable business model and operational leverage.
Market effects
Health savings account providers may see increased investor interest as HSA assets grow rapidly.
U.S. health‑benefit fintech sector could benefit from HealthEquity's performance.
Limited; primarily U.S. market focus.
Counterpoint
Rising service costs and price erosion risk could pressure margins if competitive pricing intensifies.
Key entities
- ExecutiveScott Cutler
President and CEO of HealthEquity
- ExecutiveJames Lucania
Executive Vice President and CFO of HealthEquity
